117254-07-6

Basic information

• Product Name: 4-TERT-BUTYLDIMETHYLSILYLOXY-2-DIETHYLAMINOMETHYL-2-CYCLOPENTENE-1-ONE
• Synonyms: 4-TERT-BUTYLDIMETHYLSILYLOXY-2-DIETHYLAMINOMETHYL-2-CYCLOPENTENE-1-ONE;4-TERT-BUTYLDIMETHYLSILYLOXY-2-DIETHYLAMINOMETHYL-2-CYLCOPENTENE-1-ONE;(R)-4-((tert-butyldimethylsilyl)oxy)-2-((diethylamino)methyl)cyclopent-2-enone;(R)-2-[(Diethylamino)methyl]-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-cyclopenten-1-one
• CAS NO: 117254-07-6
• Molecular Formula: C₁₆H₃₁NO₂Si
• Molecular Weight: 297.51
• Mol File: 117254-07-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-TERT-BUTYLDIMETHYLSILYLOXY-2-DIETHYLAMINOMETHYL-2-CYCLOPENTENE-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-TERT-BUTYLDIMETHYLSILYLOXY-2-DIETHYLAMINOMETHYL-2-CYCLOPENTENE-1-ONE(117254-07-6)
• EPA Substance Registry System: 4-TERT-BUTYLDIMETHYLSILYLOXY-2-DIETHYLAMINOMETHYL-2-CYCLOPENTENE-1-ONE(117254-07-6)

Safety Data

• Hazardous Substances Data: 117254-07-6(Hazardous Substances Data)

Usage

Description

4-TERT-BUTYLDIMETHYLSILYLOXY-2-DIETHYLAMINOMETHYL-2-CYCLOPENTENE-1-ONE, also known as (R)-2-[(Diethylamino)methyl]-4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-cyclopenten-1-one, is a chemical compound with a complex structure that features a cyclopentenone core, a diethylaminomethyl group, and a tert-butyldimethylsilyloxy substituent. 4-TERT-BUTYLDIMETHYLSILYLOXY-2-DIETHYLAMINOMETHYL-2-CYCLOPENTENE-1-ONE is characterized by its potential biological activities and applications in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
4-TERT-BUTYLDIMETHYLSILYLOXY-2-DIETHYLAMINOMETHYL-2-CYCLOPENTENE-1-ONE is used as a prostaglandin DP receptor agonist for its ability to modulate the activity of the DP receptor, which plays a role in various physiological processes.
Used in Ophthalmology:
In the field of ophthalmology, 4-TERT-BUTYLDIMETHYLSILYLOXY-2-DIETHYLAMINOMETHYL-2-CYCLOPENTENE-1-ONE is used as a topical antiglaucoma agent. Its agonistic effect on the prostaglandin DP receptor helps to reduce intraocular pressure, which is a common treatment goal in managing glaucoma to prevent optic nerve damage and vision loss.
The compound's specific application as a prostaglandin DP receptor agonist highlights its potential utility in developing new therapeutic strategies for glaucoma management, offering an alternative to existing treatments and potentially improving patient outcomes.

Upstream product

• 117254-03-2 (3S,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-3-methoxy-2-methylene-cyclopentanone 
• 109-89-7 diethylamine 
• 117253-98-2 (3S,4R)-3-(Methoxymethyloxy)-2-methylidene-4-(tert-butyldimethylsiloxy)cyclopentanone 
• 100017-22-9 (S)-1-[(R)-oxiran-2-yl]prop-2-enol 
• 902453-77-4 (R)-2-((S)-1-Methoxy-allyl)-oxirane 
• 117253-99-3 (3R,4S)-3-(tert-Butyl-dimethyl-silanyloxy)-4-methoxy-hex-5-enenitrile 
• 117254-00-9 (3R,4S)-3-(tert-Butyl-dimethyl-silanyloxy)-4-methoxy-hex-5-enal oxime 
• 117253-95-9 (3R,4S)-3-(tert-Butyl-dimethyl-silanyloxy)-4-methoxymethoxy-hex-5-enal 
• 117269-26-8 (3R,4S)-3-(tert-Butyl-dimethyl-silanyloxy)-4-methoxymethoxy-hex-5-enenitrile 
• 117269-27-9 (3R,4S)-3-(tert-Butyl-dimethyl-silanyloxy)-4-methoxymethoxy-hex-5-enal oxime 
• 117254-02-1 (3S,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-hydroxymethyl-3-methoxy-cyclopentanone 
• 117254-01-0 (4S,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-4-methoxy-3a,4,5,6-tetrahydro-3H-cyclopenta[c]isoxazole 
• 117253-97-1 (3S,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-hydroxymethyl-3-methoxymethoxy-cyclopentanone 
• 117253-96-0 (4S,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-4-methoxymethoxy-3a,4,5,6-tetrahydro-3H-cyclopenta[c]isoxazole 

Downstream Products

• 134005-63-3 (3R, 4R)-2-methylene-3-[(3S)-3-(tert-butyldimethylsiloxy)-3-cyclohexylprop-1-ynyl]-4-(tert-butyldimethylsiloxy)cyclopentane-1-one 
• 134053-28-4 (3S,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-3-[(S)-3-(tert-butyl-dimethyl-silanyloxy)-3-cyclohexyl-prop-1-ynyl]-2-methylene-cyclopentanone 
• 467253-91-4 [3R(1E,3R),4R]-3-[3-cyclohexyl-3-[(3-oxapent-1-yl)oxy]propyl]-4-(t-butyldimethylsiloxy)-2-methylenecyclopentanone 
• 745-65-3 ALPROSTADIL 
• 329313-94-2 (3R,4R)-2-methylene-3-[(3S)-3-tert-butyldimethylsiloxy-5-phenylpent-1-ynyl]-4-(tert-butyldimethylsiloxy)cyclopentan-1-one 
• 172320-47-7 (E)-7-{(1R,2S,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(R)-3-(tert-butyl-dimethyl-silanyloxy)-4-phenoxy-but-1-ynyl]-5-oxo-cyclopentyl}-hept-2-enoic acid butylamide 
• 161446-40-8 7-{3-(tert-butyl-dimethyl-silanyloxy)-2-[3-(tert-butyl-dimethyl-silanyloxy)-4-phenoxy-but-1-ynyl]-5-oxo-cyclopentyl}-hept-2-enoic acid tert-butyl ester 
• 210349-48-7 N-(7-{3-(tert-butyl-dimethyl-silanyloxy)-2-[3-(tert-butyl-dimethyl-silanyloxy)-4-phenoxy-but-1-ynyl]-5-oxo-cyclopentyl}-heptyl)-acetamide 
• 264204-71-9 8-{(1R,2S,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(R)-3-(tert-butyl-dimethyl-silanyloxy)-4-phenoxy-but-1-ynyl]-5-oxo-cyclopentyl}-oct-4-ynoic acid methyl ester 
• 172320-40-0 (E)-7-{(1R,2S,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(R)-3-(tert-butyl-dimethyl-silanyloxy)-4-phenoxy-but-1-ynyl]-5-oxo-cyclopentyl}-hept-2-enoic acid isopropylamide 
• 172320-52-4 (E)-7-{(1R,2S,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(R)-3-(tert-butyl-dimethyl-silanyloxy)-4-phenoxy-but-1-ynyl]-5-oxo-cyclopentyl}-hept-2-enoic acid dimethylamide 
• 210349-29-4 (2R,3S,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-3-[(R)-3-(tert-butyl-dimethyl-silanyloxy)-4-phenoxy-but-1-ynyl]-2-(8-hydroxy-octyl)-cyclopentanone 
• 210349-22-7 (2R,3S,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-3-[(R)-3-(tert-butyl-dimethyl-silanyloxy)-4-phenoxy-but-1-ynyl]-2-(7-oxo-non-5-ynyl)-cyclopentanone 
• 161446-38-4 (E)-7-{(1R,2S,3R)-3-(tert-Butyl-dimethyl-silanyloxy)-2-[(R)-3-(tert-butyl-dimethyl-silanyloxy)-4-phenoxy-but-1-ynyl]-5-oxo-cyclopentyl}-hept-2-enoic acid methyl ester 

Relevant articles and documents

Radical addition reactions to allylstannanes having substituents at C-1. Highly efficient synthesis of enantiomerically pure α-alkylcyclopentenones, the key component for synthesis of prostaglandins by the two-component coupling process

A highly efficient and practical method for the synthesis of enantiomerically pure 4-alkoxy-2-alkyl-2-cyclopenten-1-ones 1, the key component for the preparation of prostaglandins via the two-component coupling process, has been developed. The method involves the preparation of 4-alkoxy-2-methylene-3-(tributylstannyl)cyclopentan-1-one 6 from readily available 4-alkoxy-2[(diethylamino)methyl]-2-cyclopenten-1-one 5 and its reaction with alkyl radicals.

Novel preparation method and intermediate of prostaglandin

The invention provides an optically active cyclopentanone compound shown as a formula (I) and a preparation method thereof. The optically active cyclopentanone compound can be used for preparing key intermediates and derivatives thereof in prostaglandin synthesis. The invention also provides a method for synthesizing prostaglandin by using the optically active cyclopentanone compound. When the optically active cyclopentanone compound is used for synthesizing prostaglandin, the synthesis steps of prostaglandin can be remarkably shortened, the synthesis efficiency is improved, and the production cost is reduced.